Gastroenterology

Developed Formulas
Benefits
  • Improves abdominal bloating and pain

  • Helps alleviate inflammation

  • Supports intestinal barrier function

  • Antipathogenic activity

Gastroenterology
Ready to market
Gastroenterology
Clinical test
Gastroenterology
Microbac
Gastroenterology
In vitro test
Gastroenterology
Hydrosoluble powder
Gastroenterology
Allergen Free
Gastroenterology
Real time stability
Components

Lactiplantibacillus plantarum LP01 (LMG P-21021)
Lactobacillus acidophilus LA02 (DSM 21717)

Label Claim
Effective nutraceutical combination
Scientific Rationale
  • Anti-pathogenic activity

PROBIAL® Flat Belly is a probiotic food supplement designed specifically to alleviate bloating and abdominal pain associated with gut inflammation conditions. This supplement harnesses the anti-inflammatory properties of two bacterial strains: Lactiplantibacillus plantarum LP01 and Lactobacillus acidophilus LA02. These strains possess unique properties targeting immune function, mucosal inflammation and damage, as well as gut dysbiosis [1-4].

  • Lactiplantibacillus plantarum LP01 has demonstrated significant efficacy in treating and preventing gastrointestinal inflammatory disorders, including reducing bacterial overgrowth in Irritable Bowel Syndrome (IBS) [4]. It promotes a Th2- and counteracts a Th1-immune response, which is beneficial in managing these conditions [1].

  • Both LP01 and LA02 are capable of directly antagonizing specific potential nosocomial pathogens, including Klebsiella pneumoniaeE. coliStaphylococcus aureusEnterococcus faecium, and Pseudomonas aeruginosa [3].

  • Additionally, LP01 and LA02 have both been found to provide protection to epithelial cells against inflammation-induced barrier dysfunction [1,2].

The effectiveness of PROBIAL® Flat Belly is supported by a rigorous clinical study focusing on IBS-related abdominal bloating and pain. In this clinical trial, PROBIAL® Flat Belly showed remarkable efficacy in relieving pain and the main symptoms typically associated with IBS [5].

Bibliography

1. Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 2019;  7:214. Doi: 10.35248/2329-8901.19.7.214

2. Magistrelli L. et al. Probiotics May Have Beneficial Effects in Parkinson's Disease: In vitro Evidence. Front Immunol. 2019 May 7;10:969. doi: 10.3389/fimmu.2019.00969

3. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216.  DOI: 10.35248/2329-8901.20.8.216

4. Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32

5. Saggioro A. Probiotics in the treatment of Irritable Bowel Syndrome. J Clin Gastroenterol, 2004; 38(8): S104-106. DOI: 10.1097/01.mcg.0000129271.98814.e2

Associations